These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1330970)
1. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer. Rosell R; Carles J; Abad A; Ribelles N; Barnadas A; Benavides A; Martin M Invest New Drugs; 1992 Aug; 10(3):171-5. PubMed ID: 1330970 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of mitonafide in non-small cell lung cancer (NSCLC). Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of mitonafide in solid tumors. Llombart M; Poveda A; Forner E; Fernández-Martos C; Gaspar C; Muñoz M; Olmos T; Ruiz A; Soriano V; Benavides A Invest New Drugs; 1992 Aug; 10(3):177-81. PubMed ID: 1428727 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. Díaz-Rubio E; Martín M; López-Vega JM; Casado A; Benavides A Invest New Drugs; 1994; 12(4):277-81. PubMed ID: 7775127 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of Mitonafide in advanced and relapsed colorectal cancer. Abad A; Grávalos C; Font A; Molina F; Díaz-Puente MT; Fabregat X; Benavides A; Martín M Invest New Drugs; 1996; 14(2):223-5. PubMed ID: 8913845 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. Berger MZ; Kris MG; Gralla RJ; Marks LD; Potanovich LM; Dimaggio JJ; Heelan RT Am J Clin Oncol; 1991 Apr; 14(2):124-6. PubMed ID: 1851387 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of amonafide in advanced and recurrent sarcoma patients. Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of amonafide in advanced breast cancer. Scheithauer W; Dittrich C; Kornek G; Haider K; Linkesch W; Gisslinger H; Depisch D Breast Cancer Res Treat; 1991 Dec; 20(1):63-7. PubMed ID: 1813070 [TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic characterization of mitonafide in man. Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Chang AY; Tu ZN; Smith JL; Bonomi P; Smith TJ; Wiernik PH; Blum R Invest New Drugs; 1995; 13(2):137-41. PubMed ID: 8617576 [TBL] [Abstract][Full Text] [Related]
14. Phase I-II trial of concomitant continuous carboplatin (CBDCA) infusion and radiotherapy in advanced nonsmall cell lung cancer with evaluation for surgery: final report. Trodella L; Cellini N; Picciocchi A; Marano P; Balducci M; Mantini G; Turriziani A; Corbo GM; Valente S; Valentini V; Pirronti T; Granone P; Dobelbower RR Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):93-101. PubMed ID: 9054882 [TBL] [Abstract][Full Text] [Related]
15. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study. Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018 [TBL] [Abstract][Full Text] [Related]
17. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. Hainsworth JD; Thompson DS; Greco FA J Clin Oncol; 1995 Jul; 13(7):1609-14. PubMed ID: 7602349 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. Evans WK; Eisenhauer EA; Cormier Y; Ayoub J; Wierzbicki R; Laberge F; Shepherd FA J Clin Oncol; 1990 Mar; 8(3):390-5. PubMed ID: 2155309 [TBL] [Abstract][Full Text] [Related]
19. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]